Nuo Therapeutics, Inc. (AURX)
OTCMKTS · Delayed Price · Currency is USD
1.020
0.00 (0.00%)
Jul 27, 2026, 1:09 PM EST

Nuo Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4.133.311.370.610.11-
Revenue Growth
155.81%142.72%124.34%442.12%--
Gross Profit
2.72.221.060.480.09-
Operating Income
-2.22-2.52-2.46-3.17-3.32-0.09
Net Income
-2.38-2.51-2.32-3.17-3.17-0.89
Earnings Per Share
-0.05-0.05-0.05-0.08-0.08-0.03
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.260.550.280.932.051.41
Total Debt
1.10.60.160.260.34-
Net Cash (Debt)
-0.84-0.050.120.671.721.41
Net Cash Growth
---82.25%-60.78%21.32%776.26%
Net Cash Per Share
-0.02-0.000.000.020.040.05

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1.65-0.86-2.23-3.17-3.71-0.12
Capital Expenditures
-0.05-0.27-0.15-0.01-0.06-
Free Cash Flow
-1.7-1.14-2.39-3.18-3.77-0.12
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
65.46%66.94%77.82%79.28%82.88%-
Operating Margin
-53.69%-75.95%-180.04%-520.65%-2958.21%-
Pretax Margin
-57.72%-75.82%-170.21%-521.17%-2825.60%-
Profit Margin
-57.72%-75.82%-170.21%-521.17%-2825.60%-
FCF Margin
-41.07%-34.40%-174.82%-521.76%-3355.12%-

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
11.9528.6448.0139.99558.56-